Tardive dyskinesia: nondopaminergic treatment approaches.

Daniel Casey

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The continuing concern about tardive dyskinesia (TD) has stimulated a broad search for therapies for this disorder. Since neuroleptic drugs are thought to be the etiological agents, acting presumably through dopamine receptor blockade, nondopaminergic drugs have been the focus of recent study. However, no uniformly safe and effective drug treatment has been identified. Augmentation of cholinergic function is theoretically attractive, but further research is needed to develop practical and effective compounds. GABA drugs do not consistently suppress TD. The effect of benzodiazepines in TD is unclear, but these agents may be of some temporary benefit in patients with distressing symptoms. Lithium, serotonergic compounds, and numerous neuropeptides all fail to have any consistent effect in TD. Early reports of benefit with alpha- and beta-noradrenergic agents are interesting but require further study. Many other drug types have been tried without benefit. For the majority of patients, it may be best to give no drug treatment. Any drug that is capable of suppressing TD may aggravate the disorder in the long term. The potential for a spontaneous gradual remission of TD is an argument in favor of a patient, nonaggressive, and cautiously optimistic approach to this disorder.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalPsychopharmacology. Supplementum
Volume2
StatePublished - 1985
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
Lithium Compounds
Therapeutics
Spontaneous Remission
Dopamine Receptors
Neuropeptides
Benzodiazepines
gamma-Aminobutyric Acid
Cholinergic Agents
Antipsychotic Agents
Tardive Dyskinesia
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tardive dyskinesia : nondopaminergic treatment approaches. / Casey, Daniel.

In: Psychopharmacology. Supplementum, Vol. 2, 1985, p. 137-144.

Research output: Contribution to journalArticle

@article{d23f21b22e5a49799257e32beaf05cee,
title = "Tardive dyskinesia: nondopaminergic treatment approaches.",
abstract = "The continuing concern about tardive dyskinesia (TD) has stimulated a broad search for therapies for this disorder. Since neuroleptic drugs are thought to be the etiological agents, acting presumably through dopamine receptor blockade, nondopaminergic drugs have been the focus of recent study. However, no uniformly safe and effective drug treatment has been identified. Augmentation of cholinergic function is theoretically attractive, but further research is needed to develop practical and effective compounds. GABA drugs do not consistently suppress TD. The effect of benzodiazepines in TD is unclear, but these agents may be of some temporary benefit in patients with distressing symptoms. Lithium, serotonergic compounds, and numerous neuropeptides all fail to have any consistent effect in TD. Early reports of benefit with alpha- and beta-noradrenergic agents are interesting but require further study. Many other drug types have been tried without benefit. For the majority of patients, it may be best to give no drug treatment. Any drug that is capable of suppressing TD may aggravate the disorder in the long term. The potential for a spontaneous gradual remission of TD is an argument in favor of a patient, nonaggressive, and cautiously optimistic approach to this disorder.",
author = "Daniel Casey",
year = "1985",
language = "English (US)",
volume = "2",
pages = "137--144",
journal = "Psychopharmacology. Supplementum",
issn = "0179-8456",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Tardive dyskinesia

T2 - nondopaminergic treatment approaches.

AU - Casey, Daniel

PY - 1985

Y1 - 1985

N2 - The continuing concern about tardive dyskinesia (TD) has stimulated a broad search for therapies for this disorder. Since neuroleptic drugs are thought to be the etiological agents, acting presumably through dopamine receptor blockade, nondopaminergic drugs have been the focus of recent study. However, no uniformly safe and effective drug treatment has been identified. Augmentation of cholinergic function is theoretically attractive, but further research is needed to develop practical and effective compounds. GABA drugs do not consistently suppress TD. The effect of benzodiazepines in TD is unclear, but these agents may be of some temporary benefit in patients with distressing symptoms. Lithium, serotonergic compounds, and numerous neuropeptides all fail to have any consistent effect in TD. Early reports of benefit with alpha- and beta-noradrenergic agents are interesting but require further study. Many other drug types have been tried without benefit. For the majority of patients, it may be best to give no drug treatment. Any drug that is capable of suppressing TD may aggravate the disorder in the long term. The potential for a spontaneous gradual remission of TD is an argument in favor of a patient, nonaggressive, and cautiously optimistic approach to this disorder.

AB - The continuing concern about tardive dyskinesia (TD) has stimulated a broad search for therapies for this disorder. Since neuroleptic drugs are thought to be the etiological agents, acting presumably through dopamine receptor blockade, nondopaminergic drugs have been the focus of recent study. However, no uniformly safe and effective drug treatment has been identified. Augmentation of cholinergic function is theoretically attractive, but further research is needed to develop practical and effective compounds. GABA drugs do not consistently suppress TD. The effect of benzodiazepines in TD is unclear, but these agents may be of some temporary benefit in patients with distressing symptoms. Lithium, serotonergic compounds, and numerous neuropeptides all fail to have any consistent effect in TD. Early reports of benefit with alpha- and beta-noradrenergic agents are interesting but require further study. Many other drug types have been tried without benefit. For the majority of patients, it may be best to give no drug treatment. Any drug that is capable of suppressing TD may aggravate the disorder in the long term. The potential for a spontaneous gradual remission of TD is an argument in favor of a patient, nonaggressive, and cautiously optimistic approach to this disorder.

UR - http://www.scopus.com/inward/record.url?scp=0021902857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021902857&partnerID=8YFLogxK

M3 - Article

C2 - 2860657

AN - SCOPUS:0021902857

VL - 2

SP - 137

EP - 144

JO - Psychopharmacology. Supplementum

JF - Psychopharmacology. Supplementum

SN - 0179-8456

ER -